Inclusion Criteria:

- Males age 45-80 years

- Diagnosis of prostate cancer

- Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker
therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation

- Baseline AUA score< or =12

- May be on antiandrogenand/or alpha reductase therapy

- Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the
primary therapy for prostate cancer with curatives intent -

Exclusion Criteria:

- History of insulin-dependent diabetes

- Uncontrolled hypertention

- History of symptomtic hypotension (including syncope and dizziness)

- Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary
Retention

- Pre-existing prostatitis either continuous or intermittent

- Concurrent use of any other anticholinergics

- previous or concurrent usage of LHRH agonist